The SARS CoV-2 pandemic is a global health threat with high morbidity and mortality (1 to 4%) rates. COVID-19 is correlated with important immune disorders, including a “cytokine storm”. A new therapeutic approach using the immunomodulatory drug, Anti-IL6 (tocilizimub), has been proposed to regulate it. We report here the first Tunisian experience using tocilizimub in two severe cases of COVID-19 pneumonia. The diagnosis was confirmed by chest scan tomography. Biological parameters showed a high level of Interleukin-6 (IL-6) that increased significantly during hospitalization. The patients developed hypoxia, so they received intravenously 8 mg/kg body weight tocilizumab. There was a resultant decrease in the level of IL6, with clinically good evolution. Blocking the cytokine IL-6 axis is a promising therapy for patients developing COVID-19 pathology.
【저자키워드】 Cytokine storm, Tocilizumab, Case report, interleukin 6, COVID-19 infection, 【초록키워드】 COVID-19, SARS CoV-2, Evolution, Cytokine storm, COVID-19 pneumonia, pandemic, therapy, Hospitalization, hypoxia, Tocilizumab, Pneumonia, IL-6, body weight, interleukin-6, Diagnosis, IL6, tomography, cytokine, Health, interleukin, immunomodulatory, Patient, morbidity and mortality, Therapeutic approach, regulate, Biological, immune disorders, anti-IL6, SARS CoV, Severe case, COVID-19 pathology, biological parameters, intravenously, chest scan, parameter, blocking, decrease, significantly, clinically, correlated, “cytokine storm”, 【제목키워드】 Treatment, Severe COVID-19 pneumonia,